Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
10th IEEE International Conference on Healthcare Informatics, ICHI 2022 ; : 502-504, 2022.
Article in English | Scopus | ID: covidwho-2063256

ABSTRACT

Since the start of the COVID-19 pandemic, hospitals have been overwhelmed with the high number of ill and critically ill patients. The surge in ICU demand led to ICU wards running at full capacity, with no signs of demand falling. As a result, resource management of ICU beds and ventilators has been a bottleneck in providing adequate healthcare to those in need. Short-term ICU demand forecasts have become a critical tool for hospital administrators. Therefore, using the existing COVID-19 patient data, we build models to predict if a patient's health will deteriorate below safe thresholds to deem admission into ICU in the next 24 to 96 hours. We identify the most important clinical features responsible for the prediction and narrow down the health indicators to focus on, thereby assisting the hospital staff in increasing responsiveness. These models can help the hospital staff better forecast ICU demand in near real-time and triage patients for ICU admissions as per the risk of deterioration. Using a retrospective study with a dataset of 1411 COVID-19 patients from an actual hospital in the USA, we run experiments and find XGBoost performs the best among the models tested when tuning parameters for sensitivity (recall). The most important feature for the four prediction tasks is the maximum respiratory rate, but subsequent features in order of importance vary between models predicting ICU transfer in the next 24 to 48 hours and those predicting ICU transfer in the next 72 to 96 hours. © 2022 IEEE.

2.
BMC Public Health ; 21(1): 638, 2021 Apr 01.
Article in English | MEDLINE | ID: covidwho-1166899

ABSTRACT

BACKGROUND: SARS-CoV-2 has ever-increasing attributed deaths. Vital sign trends are routinely used to monitor patients with changes in these parameters preceding an adverse event. Wearable sensors can measure vital signs continuously and remotely, outside of hospital facilities, recognising early clinical deterioration. We aim to determine the feasibility & acceptability of remote monitoring systems for quarantined individuals in a hotel suspected of COVID-19. METHODS: A pilot, proof-of-concept, feasibility trial was conducted in engineered hotels near London airports (May-June 2020). Individuals arriving to London with mild suspected COVID-19 symptoms requiring quarantine, as recommended by Public Health England, or healthcare professionals with COVID-19 symptoms unable to isolate at home were eligible. The SensiumVitals™ patch, measuring temperature, heart & respiratory rates, was applied on arrival for the duration of their stay. Alerts were generated when pre-established thresholds were breeched; trained nursing staff could consequently intervene. RESULTS: Fourteen individuals (M = 7, F = 7) were recruited; the mean age was 34.9 (SD 11) years. Mean length of stay was 3 (SD 1.8) days. In total, 10 vital alerts were generated across 4 participants, resulting in telephone contact, reassurance, or adjustment of the sensor. No individuals required hospitalisation or virtual general practitioner review. DISCUSSION: This proof-of-concept trial demonstrated the feasibility of a rapidly implemented model of healthcare delivery through remote monitoring during a pandemic at a hotel, acting as an extension to a healthcare trust. Benefits included reduced viral exposure to healthcare staff, with recognition of clinical deterioration through ambulatory, continuous, remote monitoring using a discrete wearable sensor. CONCLUSION: Remote monitoring systems can be applied to hotels to deliver healthcare safely in individuals suspected of COVID-19. Further work is required to evaluate this model on a larger scale. TRIAL REGISTRATION: Clinical trials registration information: ClinicalTrials.gov Identifier: NCT04337489 (07/04/2020).


Subject(s)
COVID-19 , Quarantine , Remote Sensing Technology , SARS-CoV-2 , Adult , England , Feasibility Studies , Female , Humans , London , Male , Pandemics/prevention & control
3.
Pilot Feasibility Stud ; 7(1): 62, 2021 Mar 05.
Article in English | MEDLINE | ID: covidwho-1119445

ABSTRACT

BACKGROUND: The outbreak of SARS-CoV-2 (coronavirus, COVID-19), declared a pandemic by the World Health Organization (WHO), is a global health problem with ever-increasing attributed deaths. Vital sign trends are routinely used to monitor patients with changes in these parameters often preceding an adverse event. Wearable sensors can measure vital signs continuously (e.g. heart rate, respiratory rate, temperature) remotely and can be utilised to recognise early clinical deterioration. METHODS: We describe the protocol for a pilot, proof-of-concept, observational study to be conducted in an engineered hotel near London airports, UK. The study is set to continue for the duration of the pandemic. Individuals arriving to London with mild symptoms suggestive of COVID-19 or returning from high-risk areas requiring quarantine, as recommended by the Public Health England, or healthcare professionals with symptoms suggestive of COVID-19 unable to isolate at home will be eligible for a wearable patch to be applied for the duration of their stay. Notifications will be generated should deterioration be detected through the sensor and displayed on a central monitoring hub viewed by nursing staff, allowing for trend deterioration to be noted. The primary objective is to determine the feasibility of remote monitoring systems in detecting clinical deterioration for quarantined individuals in a hotel. DISCUSSION: This trial should prove the feasibility of a rapidly implemented model of healthcare delivery through remote monitoring during a global pandemic at a hotel, acting as an extension to a healthcare trust. Potential benefits would include reducing infection risk of COVID-19 to healthcare staff, with earlier recognition of clinical deterioration through ambulatory, continuous, remote monitoring using a discrete wearable sensor. We hope our results can power future, robust randomised trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04337489 .

SELECTION OF CITATIONS
SEARCH DETAIL